# Bicara Therapeutics Inc.: overview BCAX · Nasdaq · CIK 2023658 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bcax.md) · [Financials](/companies/bcax/financials.md) · [Filings](/companies/bcax/filings.md) · [Insiders](/companies/bcax/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.60)](/filings/0002023658-25-000109.md) | not reported | [(0.68)](/filings/0001628280-26-033429.md) | [(0.50)](/filings/0001628280-26-055765.md) | [(0.67)](/filings/0002023658-25-000109.md) | not reported | [(0.93)](/filings/0001628280-26-033429.md) | [(0.82)](/filings/0001628280-26-055765.md) | | Free cash flow | $m | [(17.2) d](/filings/0002023658-25-000109.md) | [(30.1) d](/filings/0001628280-26-022010.md) | [(28.1)](/filings/0001628280-26-033429.md) | [(25.6) d](/filings/0001628280-26-055765.md) | [(29.3) d](/filings/0002023658-25-000109.md) | [(24.1) d](/filings/0001628280-26-022010.md) | [(37.6)](/filings/0001628280-26-033429.md) | [(44.3) d](/filings/0001628280-26-055765.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(89.61)](/filings/0002023658-25-000012.md) | [(4.05)](/filings/0001628280-26-022010.md) | [(2.52)](/filings/0001628280-26-022010.md) | | Free cash flow | $m | [(46.2)](/filings/0002023658-25-000012.md) | [(74.8)](/filings/0001628280-26-022010.md) | [(107)](/filings/0001628280-26-022010.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bcax/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $215.4m | 7,255,993 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $166.4m | 5,602,970 | | Reduced −200,000 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $155.9m | 5,250,000 | | Reduced −175,000 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $121.7m | 4,100,000 | | Added +37,500 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $114.2m | 3,848,090 | | Added +1,004,383 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $94.0m | 3,171,015 | | Not compared | | [RED TREE MANAGEMENT, LLC](/funds/2055980.md) | 2026-06-30 | $93.9m | 3,163,517 | | Reduced −6,992 | | [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $89.4m | 3,010,425 | | Unchanged | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $66.4m | 3,339,218 | | Not compared | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $65.8m | 2,216,639 | | Added +442,419 | ## Recent filings [All 263 filings](/companies/bcax/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-25 | 20:58 ET | [8-K](/filings/0001628280-26-058937.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001628280-26-058937 | | 2026-08-11 | 20:46 ET | [10-Q](/filings/0001628280-26-055765.md) | Quarterly report, period 2026-06-30 | 0001628280-26-055765 | | 2026-08-11 | 11:36 ET | [8-K](/filings/0001628280-26-055500.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-055500 | | 2026-07-28 | 12:35 ET | [8-K](/filings/0001628280-26-049937.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-049937 | | 2026-06-10 | 20:05 ET | [8-K](/filings/0001628280-26-042176.md) | 5.07 Shareholder vote results | 0001628280-26-042176 | | 2026-05-21 | 21:04 ET | [8-K](/filings/0001628280-26-037377.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-037377 | | 2026-05-11 | 20:03 ET | [10-Q](/filings/0001628280-26-033429.md) | Quarterly report, period 2026-03-31 | 0001628280-26-033429 | | 2026-05-11 | 11:33 ET | [8-K](/filings/0001628280-26-033135.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-033135 | | 2026-04-27 | 11:32 ET | [DEF 14A](/filings/0001628280-26-027320.md) | Proxy statement, period 2026-04-21 | 0001628280-26-027320 | | 2026-03-30 | 21:30 ET | [10-K](/filings/0001628280-26-022010.md) | Annual report, period 2025-12-31 | 0001628280-26-022010 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-022010.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2023658 - Tickers: BCAX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.